Clinical Scorecard: Changes in Metabolic Characteristics Associated with Gastrointestinal Tract Cancers, Volume II
At a Glance
Category
Detail
Condition
Gastrointestinal tract cancers including colorectal, gastric, pancreatic, and neuroendocrine tumors
Key Mechanisms
Altered tumor microenvironment, systemic inflammation, immune suppression, metabolic reprogramming including lipid and glucose metabolism dysregulation
Target Population
Patients with colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), and gastroenteropancreatic neuroendocrine tumors
Care Setting
Oncology and specialized cancer care centers with capabilities for biomarker assessment and multimodal treatment
Key Highlights
Systemic immune-inflammation index (SII) is a prognostic biomarker predicting poor survival in colorectal cancer.
Combined biomarkers including CEA, SII, and prognostic nutritional index improve lymph node metastasis diagnosis in gastric cancer.
Triglyceride-glucose (TyG) index serves as a low-cost marker for CRC risk and a reverse prognostic biomarker in pancreatic cancer liver metastasis.
Guideline-Based Recommendations
Diagnosis
Use composite biomarkers integrating inflammatory and nutritional indices for improved diagnostic accuracy in lymph node metastasis of gastric cancer.
Employ TyG index as a screening tool for identifying high-risk individuals for colorectal cancer.
Consider remnant cholesterol levels for risk stratification and tumor grading in pancreatic neuroendocrine neoplasms.
Management
Surgical resection and cytoreductive therapy are preferred for managing liver metastasis in gastroenteropancreatic neuroendocrine tumors.
Liver-directed therapies like ablation and embolization may be used for unresectable metastatic cases.
Personalized, precision-based systemic treatments are essential for aggressive metastatic gastrointestinal cancers.
Monitoring & Follow-up
Monitor systemic immune-inflammation index and nutritional status to assess disease progression and prognosis.
Track metabolic markers such as TyG index and remnant cholesterol to evaluate tumor metabolic phenotype and aggressiveness.
Risks
Advanced disease at diagnosis is common, especially in gastric cancer, leading to poor prognosis.
Lymph node metastasis significantly worsens outcomes in gastric cancer.
Metabolic dysregulation including insulin resistance and cachexia impacts tumor progression and patient survival.
Patient & Prescribing Data
Patients with gastrointestinal tract cancers including CRC, GC, PDAC, and neuroendocrine tumors
Integration of metabolic and inflammatory biomarkers can guide early diagnosis, risk stratification, and personalized treatment strategies to improve survival and quality of life.
Clinical Best Practices
Incorporate systemic immune-inflammation and nutritional indices as composite biomarkers for better prognostic and diagnostic accuracy.
Utilize accessible metabolic indices such as TyG and remnant cholesterol for risk assessment and monitoring.
Adopt multimodal treatment approaches combining surgery, liver-directed therapies, and systemic options tailored to tumor type and metastatic status.
Encourage prospective, multicenter studies to standardize biomarker cut-offs and validate translational utility.
Consider tumor microenvironment and metabolic reprogramming in therapeutic resistance and treatment planning.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
